<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136796</url>
  </required_header>
  <id_info>
    <org_study_id>AZVCR 9307_4</org_study_id>
    <nct_id>NCT03136796</nct_id>
  </id_info>
  <brief_title>Glycocalyx Damage and Beta-lactam Antibiotics in Surgical Critically Ill</brief_title>
  <official_title>Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GCX damage and its relationship to pharmacodynamics and pharmacokinetics of beta lactam
      antibiotics in critically ill Hypothesis to be tested: GCX damage impairs pharmacodynamics
      and pharmacokinetics of beta-lactam antibiotics in critically ill patients. There is
      correlation between GCX damage and insufficient beta lactam levels in patients with commonly
      used dosing. The aim of the study: Evaluation of relationship between GCX damage and
      pharmacodynamics and pharmacokinetics of beta-lactam antibiotics in critically ill. Type of
      the study: Observational. Subjects: Adult patients admitted to ICU with beta-lactam
      antibiotic therapy (meropenem or piperacillin/tazobactam empirically or based on culture
      results). Sample size calculation: 20 patients (expected correlation coefficient 0,6, alpha
      error = 0,05) will lead to power study = 0,89. Intervention: none. Data to be recorded and
      analyzed: Demographics, type of patients (trauma, post surgical, medical, after cardiac
      arrest), severity score - Apache II, SOFA, fluid balance, a presence of delirium, clinical
      outcome, sublingual microcirculation by SDF imaging will be recorded three times during
      antibiotic treatment at the time points for blood samples required for pharmacodynamics and
      pharmacokinetic analysis, microcirculatory data and Perfused Boundary Region.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Anticipated">May 2, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasmatic concentrations of antibiotics</measure>
    <time_frame>6 months</time_frame>
    <description>Concentration of antibiotics will be assessed in plasma after their administration in mmol/l to calculate their pharmacokinetic and pharmacodynamic profile.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perfused Boundary Region</measure>
    <time_frame>6 months</time_frame>
    <description>PBR is a parameter obtained automatically by specialized software after examination of the sublingual microcirculation by handheld microscope that describes the amount of glycocalyx destruction.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Critical Illness</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Patients will receive intravenous antibiotics eighter empirically or based on a culture.</description>
    <other_name>Piperacillin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients admitted to ICU due to sepsis or polytrauma in need for intravenous
        antibiotic therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients admitted to ICU with beta-lactam antibiotic therapy (meropenem or
             piperacillin/tazobactam empirically or based on culture results).

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <state>Třebeš</state>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Astapenko D, Jor O, Lehmann C, Cerny V. In situ assessment of the renal microcirculation in mechanically ventilated rats using sidestream dark-field imaging. J Microsc. 2015 Feb;257(2):161-5. doi: 10.1111/jmi.12198. Epub 2014 Dec 24.</citation>
    <PMID>25545609</PMID>
  </reference>
  <reference>
    <citation>Arora N, Islam S, Wafa K, Zhou J, Toguri JT, Cerny V, Lehmann C. Evaluation of iris functional capillary density in experimental local and systemic inflammation. J Microsc. 2017 Apr;266(1):55-59. doi: 10.1111/jmi.12518. Epub 2017 Jan 19.</citation>
    <PMID>28102536</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Hradec Kralove</investigator_affiliation>
    <investigator_full_name>Vladimir Cerny</investigator_full_name>
    <investigator_title>Vladimir Cerny, MD, PhD, FCCM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

